Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. (Q54304254)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 December 2014

edit

Language	Label	Description	Also known as
English	Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.	scientific article published on 5 December 2014

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

title

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

author name string

Mark A Dickson

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Michael S Gordon

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Gerald Edelman

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Johanna C Bendell

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Ragini R Kudchadkar

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Patricia M LoRusso

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Stuart H Johnston

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Douglas O Clary

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

Gary K Schwartz

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

publication date

5 December 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

published in

Investigational New Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

volume

33

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

page(s)

349-356

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25476894

retrieved

27 May 2018

reference URL

http://europepmc.org/abstract/MED/25476894

cites work

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS10637-014-0191-5

retrieved

21 January 2018

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25476894

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of Raf kinases in malignant transformation.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25476894

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ras oncogenes in human cancer: a review

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25476894

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25476894

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25476894

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-014-0191-5

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/filhefhon5giljx3n5gpkt7hw4

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

Fatcat ID

release_filhefhon5giljx3n5gpkt7hw4

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/filhefhon5giljx3n5gpkt7hw4

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

25476894

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/filhefhon5giljx3n5gpkt7hw4

retrieved

30 July 2022

based on heuristic

mapped directly with Wikidata item

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54304254&oldid=2212415887"